Cancer is essentially the uncontrolled growth of certain cells in the body that crowd out normal cells over time. When cells in the breast begin to grow out of control it may lead to breast cancer. These cells generally form a tumor that can felt as a lump, which can further be confirmed using a mammogram. The tumor is malignant if the cells can grow into surrounding tissues or spread to other parts of the body. Breast cancer occurs almost entirely in women, though men can also contract breast cancer. Mutations in DNA can cause normal breast cells to become cancerous cells. Some DNA changes are passed on from parents and can significantly increase the threat for breast cancer.

The global Breast Cancer Therapeutics market was pegged at US$ 24.68 billion in 2021. The market is expected to witness a CAGR of 13.80 % from 2022 to 2030.

Globally breast cancer is the most common cancer in women, with a prevalence of around 1.7 million in 2012, the second-most common cancer overall. This represents 12% of all new cancer cases and 25% of all cancers in women. Belgium had the topmost rate of breast cancer, followed by Denmark and France, respectively. Marginally less number of cases of breast cancer were diagnosed in less developed countries. The highest occurrence of this type of cancer was in Northern America and Oceania, whereas the lowest incidence rate in Asia and Africa.

To access the Sample PDF of this research study, please request here: https://growthplusreports.com/inquiry/request-sample/breast-cancer-therapeutics-market/7993

Key Players:
Novartis AG  
Pfizer Inc
Oncogenex
Apthera Inc
Astellas
BioNumerik Pharmaceuticals   
Oncothyreon Inc
Bipar Sciences  
Eli Lilly and Company
Novartis AG

by Cancer Type  
Hormone Receptor
HER2+
Triple Negative

by Therapy Type 
Targeted Therapy     
Hormonal Therapy
Chemotherapy
Immunotherapy
Browse the full report now: https://growthplusreports.com/report/breast-cancer-therapeutics-market/7993